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Soluble guanylate cyclase (sGC), the intracellular receptor
for the ubiquitous biological messenger NO, exists as het-
erodimer consisting of an α- and β-subunit. sGC contains
a non-covalently linked heme moiety that is crucial for the
NO-induced enzyme activation. This heme is bound to
the β-subunit via the axial ligand His-105 and the recently
identified counterparts of the heme propionic acids, Tyr-
135 and Arg-139.
The latter two residues form, together with the invariant
Ser-137, the unique heme binding motif Tyr-X-Ser-X-Arg
which was very recently confirmed by crystallization stud-
ies of a prokaryotic homologue of the sGC heme binding
domain. The aim of the present study was to investigate
the influence of the invariant Ser-137 on the sGC heme
binding capability and the enzyme activation in the pres-
ence of NO and the non-NO sGC-activators BAY 41-2272
and BAY 58-2667 respectively. Therefore, we replaced this
residue with Ala and investigated the activation profile of
the mutant sGC by transient transfection into the novel
cGMP reporter cell line using BAY 41-2272, BAY 58-2667,
NO and ODQ as experimental tools.
The mutant sGC was activated by BAY 41-2272. A syner-
gistic increase in sGC activity was observed in the presence
of additional NO. However, this well known synergism of
both heme-dependent sGC-activators was less than
observed for the wild-type enzyme. Activation of the Ser-
137-Ala-mutant by DEA/NO alone was markedly dimin-
ished. BAY 58-2667-induced sGC activation was much
stronger with the Ser-137-mutant compared to the wild-
type enzyme but the potentiating effect of ODQ on this
activation was negligible compared to the wild-type
enzyme.
In summary our results show for the first time that Ser-137
is involved in binding and stabilizing the sGC heme moi-
ety and might be also involved in the intramolecular sig-
nal transduction upon NO binding leading to sGC
activation.
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